
SUSAN L. HOGUE, PharmD, MPH
Head, Value Insight and Access Strategy

Education

MPH, Health Policy and Administration, University of North Carolina, Chapel Hill, NC
Fellowship, Pediatric Pharmacotherapy and Pharmacokinetics, University of Tennessee, Memphis, TN
Residency, Pediatric Pharmacotherapy, University of Tennessee, Memphis, TN
PharmD, University of Kentucky, Lexington, KY
BS, Pharmacy, University of North Carolina, Chapel Hill, NC

Summary of Professional Experience

Susan Hogue, PharmD, MPH, is the Head of the Value Insight and Access Strategy group at RTI-HS. Dr. Hogue has more than 18 years of industry experience, including leadership roles in both Global Health Outcomes and US Health Outcomes at GlaxoSmithKline. Dr. Hogue's considerable experience encompasses all aspects of outcomes research and market access evidence generation and implementation, including health economic and outcomes strategy development, payer value proposition development and communication, market access strategy development, payer research, endpoint determination in clinical trial design, and value dossier and market access toolkit development. Dr. Hogue has broad therapeutic expertise, including in the areas of neuroscience (e.g., depression, migraine, smoking cessation, restless legs syndrome, epilepsy, bipolar disorder), HIV, urology, pediatrics, and osteoporosis. In her RTI-HS role, she leads a team of specialists responsible for providing clients with effective, tailored solutions to support market access for medicines, diagnostics, and devices. Additionally, Dr. Hogue serves as an adjunct assistant professor at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.

Employment Chronology

2014 to present	Head, Value Insight and Access Strategy	RTI Health Solutions RTI International
2010 to 2014	Senior Director, Market Access and Outcomes Strategy	RTI Health Solutions RTI International
2005 to 2010	Director, US Health Outcomes, Cardiovascular, Metabolic, Urology, & Neuroscience	GlaxoSmithKline Research Triangle Park, NC
2002 to 2005	Director, Global Health Outcomes, Psychiatry	GlaxoSmithKline Research Triangle Park, NC
2000 to 2002	Principal Health Outcomes Scientist, Global Health Outcomes	GlaxoSmithKline Research Triangle Park, NC
1998 to 2000	Senior Health Outcomes Scientist, Global Health Outcomes	GlaxoWellcome Research Triangle Park, NC

1996 to 1998	Pharmacoeconomic Research Scientist, US Medical Affairs	GlaxoWellcome Research Triangle Park, NC
1994 to 1996	Associate Pharmacoeconomic Scientist, US Medical Affairs	GlaxoWellcome Research Triangle Park, NC
1992 to 1994	Senior Drug Information Associate	Glaxo Research Triangle Park, NC

Publications

White MV, Silvia S, Muniz R, Herrem C, Hogue SL. Prevalence and triggers of anaphylactic events in schools. *Allergy Asthma Proc.* 2017; 38:286–293.

Brogan AP, DeMuro C, Barrett AM, D'Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. *J Manag Care Spec Pharm.* 2017 Feb;23(2):124-34.

White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S..Anaphylaxis in Schools: Results of the EPIPEN4SCHOOLS Survey Combined Analysis.. *Pediatr Allergy Immunol Pulmonol.* 2016 Sep 1;29(3):149-154

Hogue SL, Goss D, Hollis K, Silvia S; White MV. Training and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools® pilot survey. *J Asthma Allergy.* 2016;9:109-15.

White MV, Goss D, Hollis K, Millar K, Silvia S, ..., Hogue SL, et al. Anaphylaxis triggers and treatments by grade level and staff training: findings from the EPIPEN4SCHOOLS pilot survey. *Pediatric Allergy, Immunology, Pulmonology.* 2016;29:80-5.

Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, et al. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ≥ 2 . *SAGE Open Med.* 2016;3: 2050312115613350

Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. *Clinicoecon Outcomes Res.* 2015;7:451-62.

Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. *Am J Ophthalmol.* 2015;160(4):725-31.

White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, et al. EpiPen4Schools pilot survey: Occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. *Allergy Asthma Proc.* 2015;36(4):306-12.

Kruep EJ, Phillips E, Hogue S, Eaddy M. Early symptom improvement and discontinuation of 5- α -reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH). *Ann Pharmacother.* 2014;48:343-8.

von Schéele B, Fernandez M, Hogue SL, Kwong WJ. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. *Ann Pharmacother.* 2013;47(5):671-85.

Fernandez MM, von Schéele B, Hogue S, Kwong WJ. Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation. *Am J Cardiovasc Drugs.* 2013;13(2):87-102.

Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. *Int J Nephrol Renovasc Dis.* 2012;5:151-63.

Pettaway CA, Lamerato LE, Eaddy MT, Edwards, JK, Hogue SL, Crane MM. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. *BJU Int.* 2011;108(8):1302-8.

Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. The economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia. *Am Health Drug Benefits.* 2011;4:155-62.

Lamerato LE, Kruep EJ, Hogue SL, Chaudhari SL, Eaddy MT. Outcomes with early versus delayed 5ARIs for benign prostatic hyperplasia. *Am J Pharm Benefits.* 2011;3(6):e127-34.

Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. *Curr Med Res Opin.* 2009;25(11):2663-9.

Naslund M, Regan TS, Ong C, Hogue SL. 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. *Am J Manag Care.* 2008;14(5 suppl 2):S148-53.

Naslund M, Eaddy MT, Kruep EJ, Hogue SL. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. *Am J Manag Care.* 2008;14(5 suppl 2):S167-71.

McLaughlin T, Hogue SL, Stang PE. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. *Am J Ther.* 2007;14(2):221-5.

Fishman PA, Stang PE, Hogue SL. Impact of comorbid attention deficit disorder on the direct medical costs of treating adults with depression in managed care. *J Clin Psychiatry.* 2007;68(2):248-53.

Stang P, Young S, Hogue S. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. *Am J Ther.* 2007;14(1):20-4.

Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. *J Clin Psychiatry.* 2006;67(2):204-10.

Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. *Am J Ther.* 2007;14(3):241-6.

Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. *J Affect Disord.* 2006;90(2-3):217-21.

Puska PM, Barrueco M, Roussos C, Hider A, Hogue S. The participation of health professionals in a smoking-cessation programme positively influences the smoking cessation advice given to patients. *Int J Clin Pract.* 2005;59(4):447-52.

Fehnel SE, Bann CM, Hogue SL, Kwong WJ, Mahajan SS. The development and psychometric evaluation of the Motivation and Energy Inventory (MEI). *Qual Life Res.* 2004;13(7):1321-36.

Hoffman LH, Strutton DR, Stang PE, Hogue SL. Impact of smoking on respiratory illness-related outpatient visits among 50- to 75-year-olds in the United States. *Clin Ther.* 2002;24(2):317-24.

Miller DP, Villa KF, Hogue SL, Sivapathasundaram D. Birth and first-year costs for mothers and infants attributable to maternal smoking. *Nicotine Tob Res.* 2001;3(1):25-35.

Orme ME, Hogue SL, Kennedy LM., Paine AC, Godfrey C. Development of the health and economic consequences of smoking interactive model. *Tob Control*. 2001;10(1):55-61.

Fleisher LA, Hogue SL, Colopy M, Twersky RS, Warner DS, Jamerson BJ, et al. Does functional ability in the postoperative period differ between remifentanyl- and fentanyl-based anesthesia? *J Clin Anesth*. 2001;13(6):401-6.

Twersky RS, Jamerson BJ, Warner DS, Fleisher LA, Hogue SL. Hemodynamics and emergence profile of remifentanyl versus fentanyl prospectively compared in a large population of surgical patients. *J Clin Anesth*. 2001;13(6):407-16.

Hogue SL, Reese PR, Colopy M, Fleisher LA, Tuman KJ, Twersky RS, et al. Assessing a tool to measure patient functional ability after outpatient surgery. *Anesth Analg*. 2000;91(1):97-106. [Also published in Spanish language edition of *Anesth Anag*. 2002 Dec].

Reese PR, Hogue SL, Philip BK, Niecko T. Cost analysis of remifentanyl and alfentanil in laparoscopic outpatient surgery. *Am J Anesth*. 2000;27:479-83.

Hogue SL, Reese PR, Munshi O, Young TL. Cost analysis of remifentanyl and fentanyl neurosurgical anesthesia. *Am J Health Syst Pharm*. 1999;56(6):551-4.

Hogue SL, Phelps SJ. Evaluation of three theophylline dosing equations for use in infants up to one year of age. *J Pediatr*. 1993;123(4):651-6.

Reiter PD, Hogue SL, Phelps SJ. Ability of three pharmacokinetic equations to predict steady state serum theophylline concentrations in pediatric patients. *Ther Drug Monit*. 1992;14(5):354-9.

Cochran EB, Hogue SL. Prediction of serum albumin concentration after albumin supplementation in pediatric patients receiving parenteral nutrition. *Clin Pharm*. 1991;10(9):704-6.

Posters and Presentations

Brogan AP, Guptill JT, Runken MC, Hogue S. US payer needs for value demonstration for IGG therapies. Poster presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 23-25, 2016. Washington, DC. [abstract] *Value Health* 2016;19(3):A254.

Hogue SL, Silvia S, Hollis K, Wooddell MJ, Goss D, Odom D, et al. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. *J Allergy Clin Immunol*. 2016;137(2):AB52.

White MV, Silvia S, Hollis K, Wooddell MJ, Goss D, ..., Hogue SL, et al. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. *J Allergy Clin Immunol*. 2016;137(2):AB52.

Silvia S, Hollis K, Wooddell MJ, Hogue SL, White MV. The EpiPen4Schools® survey: prevalence and triggers of anaphylactic events in large US school districts. Slides presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting; November 5-9, 2015. San Antonio, TX.

Hogue S, Brogan AP, Croft E. Orphan and ultra-orphan technologies: European and Australian payer perceptions. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] *Value Health*;18:A681.

Hogue SL, Hollis K, Silvia S, Wooddell MJ. The EpiPen4Schools® survey: staff training and use of epinephrine auto-injectors for the treatment of anaphylaxis in large US school districts. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] *Value Health*. 2015;18:A505.

Hogue S, Brogan AP, DeMuro C, D'Alessio D, Bal V. Patient reported outcomes (PRO) in postprogression oncology: implications in health technology assessments (HTA) & payer decision making. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] *Value Health*. 2015;18(7):A487-8.

Hogue S, Brogan AP, DeMuro C, Barrett A, D'Alessio D, Bal V. Influence of patient-reported outcomes (PRO) on market access decisions in markets with centralized healthcare systems. Poster presented at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; November 7-11, 2015. Milan Italy. [abstract] *Value Health*. 2015;18:A548.

White MV, Silvia S, Hollis K, Wooddell MJ, Hogue SL. EpiPen4Schools® survey: characteristics and treatment of anaphylactic events in a US school setting. Poster presented at the Eastern Allergy Conference; May 28-31, 2015. Palm Beach, FL.

Wooddell M, Goss D, Hollis K, Millar K, Silvia S, ..., Hogue SL, et al. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools® survey. *J Allergy Clin Immunol*. 2015;135(suppl 2):AB212.

White MV, Goss D, Hollis K, Millar K, Silvia S, ..., Hogue S, et al. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers. *J Allergy Clin Immunol*. 2015;135(suppl 2):AB212.

Hogue SL, Bennett ME, Goss D, Hollis K, Millar K, Silvia S, et al. Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools® survey. *J Allergy Clin Immunol*. 2015;135(suppl 2):AB212.

Hogue SL, Brogan AP, Croft E. Orphan and ultra-orphan technologies in the new era of payment reform: United States payer Perceptions. Poster presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-20, 2015. Philadelphia, PA. [abstract] *Value Health*. 2015;18:A1-A333.

Hogue S, Bennett ME, Goss D, Hollis K, Millar K, Silvia S, et al. Availability and use of epinephrine auto-injectors for the treatment of anaphylaxis: results from the EpiPen4schools survey. Poster presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-20, 2015. Philadelphia, PA. [abstract] *Value Health*. 2015;18:A1-A333.

Brogan AP, Hogue SL, Mordin MM, Kwong J. United States decision maker perceptions of data from observational studies and other health economics and outcomes research. Poster presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-20, 2015. Philadelphia, PA. [abstract] *Value Health*. 2015;18:A1-A333.

Hogue SL, Brogan AP, DeMuro C, Barrett A, D'Alessio D, Bal V. Influence of patient-reported outcomes on market access decisions in decentralized markets (Brazil, Italy, Spain, and the United States). Poster presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-20, 2015. Philadelphia, PA. [abstract] *Value Health*. 2015;18:A1-A333.

Doward LC, Hojbjerre L, DeMuro-Mercon CJ, Hogue SL, Fernandez MM, Barrett AM, et al. Influence of patient-reported outcomes on regulatory, HTA and market access decisions: obesity and diabetes case examples. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting; May 18, 2015. Philadelphia, PA.

Hogue SL, Bennett ME, Goss DS, Hollis KA, Millar K, Silvia S, et al. Availability and use of epinephrine auto-injectors for the treatment of anaphylaxis: results from the EpiPen4Schools® survey. Presented at International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] *Value Health*. 2015;18:A178.

Mauskopf JA, Hogue SL, Brogan AP. Competitive bidding for therapeutically-equivalent branded pharmaceuticals: promise or threat? Presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting; May 20, 2015. Philadelphia, PA.

Hogue S, Scott A, van Amerongen D, Hollis K, McLeod L, Brogan AP. Payer and decision maker use of observational studies for health care reimbursement decisions. Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013. New Orleans, LA.

Copley-Merriman C, Hogue S, Olanrewaju B. Systematic literature review of the temporal relationship between NSAID use and gastrointestinal, cardiovascular, or renal events. Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013. New Orleans, LA.

Mordin MM, Hogue SL, Barrows SM, van Amerongen D. Safe and effective versus reasonable and necessary: is the deck stacked against devices? Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013. New Orleans, LA.

Lin P, Shah M, Davis A, Hogue S. Comparative economic evaluation of dutasteride versus finasteride for Medicare-aged men with benign prostatic hyperplasia. Poster presented at the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; April 2008. Toronto, Ontario, Canada.

Stang P, Hogue SL, McLaughlin TP. Once daily vs twice daily bupropion: comparison of medication persistence in elderly patients treated for depression. Poster presented at the Academy of Managed Care Pharmacy; April 2006. Seattle, WA.

Fehnel SE, Hill CD, Hogue SL. Patient-perceived differences among commonly used antidepressants: a web-based survey. Poster presented at the European Congress of Psychiatry; March 2006. Nice, France.

Stang P, Hogue S, McLaughlin T. Once daily vs twice daily bupropion: comparison of medication persistence in patients treated for depression. Poster presented at the US Psychiatric and Mental Health Congress; November 2005. Las Vegas, NV.

Fehnel SE, Hill CD, Hogue SL. Patient-perceived differences among commonly used antidepressants: a web-based survey. Poster presented at the US Psychiatric and Mental Health Congress; November 2005. Las Vegas, NV.

Fehnel SE, Wills MM, Edin HE, Hogue SL. Psychometric evaluation of the Motivation and Energy Inventory - Short Form (MEI-SF). Platform presented at the International Society for Quality of Life Research; October 2005. San Francisco, CA.

Fehnel SE, Wills MM, Edin HE, Hogue SL. Psychometric evaluation of the Motivation and Energy Inventory - Short Form (MEI-SF). Poster presented at the European College of Neuropsychopharmacology; October 2005. Amsterdam, The Netherlands.

Nelson C, Wightman DS, VanMeter SA, Hampton KD, Richard NE, Hogue SL. Impact on energy and quality of life following treatment with once daily Bupropion XL for major depressive disorder. Poster presented at the New Clinical Drug Evaluation Unit; June 2005. Boca Raton, FL.

Williams V, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. *J Psychopharmacol.* 2007;21(suppl.):A39.

Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant induced sexual dysfunction in Europe: a preliminary investigation. Poster presented at the European College of Neuropsychopharmacology; October 2004. Stockholm, Sweden.

Earnshaw SR, Krishnan A, Hogue SL, Williams Jr JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2004. Arlington, VA.

Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant induced sexual dysfunction (ADSD) in Europe: a preliminary investigation. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2004. Washington DC.

Fehnel SE, McLeod L, Hogue SL. Responsiveness of the Motivation and Energy Inventory (MEI). Poster presented at the International Society for Quality of Life Research; 2003.

Krishnan AA, Chang L, Hogue S. The impact of augmentation and switching on costs of treatment of depression. Poster presented at the American Psychiatric Association; May 2003. San Francisco, CA.

Krishnan AA, Chang L, Hogue S. The burden of depression in a managed care population. Poster presented at the American Psychiatric Association; May 2003. San Francisco, CA.

Krishnan AA, Chang L, Hogue S. The impact of chronic illnesses on risk of developing depression. Poster presented at the American Psychiatric Association; May 2003. San Francisco, CA.

Fehnel SE, McLeod LD, Pendergast K, Hogue SL, Harrison DJ, Mahajan, SS. Further psychometric evaluation of the Motivation and Energy Inventory (MEI). Poster presented at the International Society for Quality of Life Research; November 2002. Orlando, FL.

Giuntini C, Barrueco M, Astbury C, Hider AE, Hogue SL. Involvement of healthcare professionals in a smoking cessation programme positively benefits attitudes towards smoking. Poster presented at the Society for Research on Nicotine and Tobacco; September 2001. Paris, France.

Roussos C, Aigner K, Astbury C, Hider A, Hogue SL. Involvement of healthcare professionals in a smoking cessation programme positively benefits attitudes towards smoking. Poster presented at the European Respiratory Society; September 2001. Berlin, Germany.

Gorecka D, Puska P, Astbury C, Hider A, Hogue SL. Involvement of healthcare professionals in a smoking cessation programme has a positive benefit on their attitudes towards smoking. Platform presented at the World Organization of National Colleges, Academies (Primary Care Congress); June 2001. Tampere, Finland.

Bölcskei PL, Gorecka D, Perruchoud AP, Puska P, Astbury C, ..., Hogue SL, et al. Effectiveness and tolerability of Zyban™ as an aid to smoking cessation in a population of healthcare professionals - a multicountry study. Platform presented at the International Council of Nurses; June 2001. Copenhagen, Denmark.

Hogue SL, Orme ME, Boler AF. Smoking cessation effects on lung cancer: results of the health and economic consequences of smoking model. Poster presented at the 2nd European Conference on the Economics of Cancer; September 2000. Brussels, Belgium.

Orme ME, Hogue SL, Boler AF, Browning DC. Smoking cessation in the Netherlands: results of the health and economic consequences of smoking model. Platform presented at the World Congress on Lung Health and 10th ERS Annual Congress; August 2000. Florence, Italy.

Browning DC, Hogue SL, Orme ME, Boler AF. Cost-effectiveness of Zyban for smoking cessation in the United Kingdom. Poster presented at the 11th World Conference on Tobacco or Health; August 2000. Chicago, IL.

Hogue SL, Orme ME, Boler AF. Smoking cessation effects on heart disease in France: results of the health and economic consequences of smoking model. Poster presented at the 11th World Conference on Tobacco or Health; August 2000. Chicago, IL.

Hogue SL, Orme ME, Boler AF, Kennedy LM. Health and economic consequences of smoking in Germany. Poster presented at the 11th World Conference on Tobacco or Health; August 2000. Chicago, IL.

Hogue SL, Orme ME, Boler AF, Browning DC. Smoking cessation effects on COPD in the United Kingdom: results of the health and economic consequences of smoking model. Poster presented at the 11th World Conference on Tobacco or Health; August 2000. Chicago, IL.

Hogue SL, Orme ME, Boler AF. Health and economic consequences of smoking in Poland. Poster presented at the 11th World Conference on Tobacco or Health; August 2000. Chicago, IL.

Sweeny SF, Hogue SL, Ricci JF. The development of the motivation and energy inventory. Platform presented at the Drug Information Association; April 2000. Hilton Head, SC.

Hogue S, Paine A, Orme M. Health and economic consequences of smoking in the UK. (Poster presented at the Society for Research on Nicotine and Tobacco; November 1999. London, England.

Hogue S, Hahn, B, Paine A, Orme M. Cost-effectiveness of Zyban in the Netherlands. Poster presented at the Society for Research on Nicotine and Tobacco; November 1999. London, England.

Orme M, Paine A, Hogue S. Development and preliminary results of the health and economic consequences of smoking model. Platform presented at the International Society for Pharmacoeconomics and Outcomes Research European Conference; November 1999. Edinburgh, Scotland. [abstract] *Value Health*. 1999;2(5):358-9.

Hogue, SL, Nielsen K. The cost benefit of smoking cessation regimens. Poster presented at the Smoke Free 21st Century: 2nd European Conference on Tobacco or Health: 1st Iberoamerican Conference on Tobacco or Health; February 1999. Las Palmas, Canary Islands, Spain.

Tuman, KJ, Colopy M, Fleisher, LA, Glass PSA., Hogue SL, Roizen MA, et al. Effect of patient expectations on postoperative experience and satisfaction. Poster presented at the American Society of Anesthesiology; October 1999. Dallas, TX. [abstract] *Anesthesiology*. 1999;91(3A):A1221.

Hogue SL, Young TL, Jamerson BD, Moore DM. Costs, efficacy, and safety of 3 propofol/remifentanyl regimens administered in a total intravenous anesthesia technique. Platform presented at the Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists; December 1997. Atlanta, GA. [abstract] *Am J Health Promot*. 1997.

Munshi OD, Reese PR, Hogue SL, Warner DS, Young W, Hindman BJ. Neurosurgeon and anesthesiologist ratings of the quality of emergence from neuroanesthesia with remifentanyl versus fentanyl. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy; November 1997. Phoenix, AZ. [abstract] *Pharmacotherapy*. 1997;17:A171.

Hogue SL, Young TL, Jamerson BD, Philip B. Costs and outcomes associated with remifentanyl and alfentanil administered with propofol for outpatient anesthesia. Poster presented at the Annual Meeting of the American College of Clinical Pharmacy; November 1997. Phoenix, AZ. [abstract] *Pharmacotherapy*. 1997;17:A170.

Tooley JF, Hogue SL, Osterhaus JT, Silver M, Kleoudis CS, Robinson M, Earnest D. Ranitidine improves quality of life in heartburn subjects who self-medicate with antacids. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1996. Seattle, WA. [abstract] *Am J Gastroenterol*. 1996;91:A444.

Reese PR, Monk T, Mingus M, Gold M, Hogue SL, Jenkins WL. Patient comfort during block placement using remifentanyl versus propofol as adjuncts to regional anesthesia. Poster presented at the Annual Meeting of the American Association of Nurse Anesthetists; August 1996. Philadelphia, PA.

Hogue SL, Osterhaus JT. Health care resource use and direct medical costs associated with digoxin withdrawal in stable, mild to moderate CHF subjects. Platform presented at the Annual Meeting of the American College of Clinical Pharmacy; August 1996. Nashville, TN. [abstract] *Pharmacotherapy*. 1996;16:A126.

Reiter PD, Hogue SL, Phelps SJ. Ability of three pharmacokinetic equations to predict steady state theophylline clearance in pediatric patients. Platform presented at the Annual Meeting of the American College of Clinical Pharmacy; August 1991. Minneapolis, MN. [abstract] *Pharmacotherapy*. 1991.

Hogue SL, Wideman SD, Phelps SJ. Evaluation of three theophylline dosing equations in infants < 1 year of age. Encore poster presented at the Annual Meeting of the American College of Clinical Pharmacy; August 1991. Minneapolis, MN. [abstract] *Pharmacotherapy*. 1991.

Hogue SL, Wideman SD, Phelps SJ. Evaluation of three theophylline dosing equations in infants < 1 year of age. Platform presented at the Society of Pediatric Research Meeting; April 1991. New Orleans, LA.

Hogue SL, Wideman SD, Phelps SJ. Evaluation of three theophylline dosing equations in infants < 1 year of age. Platform presented at the Southern Society for Pediatric Research Meeting; February 1991. New Orleans, LA. [abstract] *Clin Res*. 1990;38:982A.

Rayburn MS, Hogue SL, Phelps SJ. Comparison of two theophylline assays in pediatric patients. Platform presented at the Southern Society for Pediatric Research Meeting; February 1991. New Orleans, LA. [abstract] *Clin Res*. 1990;38:969A.

Cochran EB, Hogue SL. Serum albumin response to albumin supplementation. Platform presented at the Southern Society for Pediatric Research Meeting; January 1990. New Orleans, LA. [abstract] *Clin Res*. 1990;38:45A.

Hughes JA, Goldsmith TL, Barker DE, Hogue SL, Chandler MHH. The effect of blood storage on the clearance of esmolol. Poster presented at the 23rd Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists; December 1988. Dallas, TX.

Book Chapters

Hogue SL, Phelps SJ. Pharmacokinetically-based drug interactions in the pediatric patient. In Yaffe SJ, Aranda JV, editors. *Pediatric pharmacology*. 2nd ed. Philadelphia, PA: WB Saunders Co.; 1992. Chapter 51.

Updated May 2017